These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 22005217

  • 21. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, Chessari S, Lanzarotti C, Jordan K, Aapro M.
    Ann Oncol; 2018 Feb 01; 29(2):452-458. PubMed ID: 29092012
    [Abstract] [Full Text] [Related]

  • 22. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Schwartzberg L, Morrow G, Balu S, Craver C, Gayle J, Cox D.
    Curr Med Res Opin; 2011 Aug 01; 27(8):1613-22. PubMed ID: 21696263
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
    Karthaus M, Tibor C, Lorusso V, Singh-Arora R, Filippov A, Rizzi G, Borroni ME, Rossi G, Grunberg SM.
    Support Care Cancer; 2015 Oct 01; 23(10):2917-23. PubMed ID: 25724407
    [Abstract] [Full Text] [Related]

  • 24. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.
    Breast Cancer Res Treat; 2009 Feb 01; 113(3):529-35. PubMed ID: 18327706
    [Abstract] [Full Text] [Related]

  • 25. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
    Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S.
    Ann Oncol; 2014 Jul 01; 25(7):1328-1333. PubMed ID: 24603643
    [Abstract] [Full Text] [Related]

  • 26. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
    Kosaka Y, Tanino H, Sengoku N, Minatani N, Kikuchi M, Nishimiya H, Waraya M, Katoh H, Enomoto T, Sato T, Kuranami M, Watanabe M.
    Support Care Cancer; 2016 Mar 01; 24(3):1405-11. PubMed ID: 26349772
    [Abstract] [Full Text] [Related]

  • 27. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB.
    Clin Adv Hematol Oncol; 2004 May 01; 2(5):284-9. PubMed ID: 16163194
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM.
    Future Oncol; 2006 Oct 01; 2(5):591-602. PubMed ID: 17026451
    [Abstract] [Full Text] [Related]

  • 30. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    Boccia R, O'Boyle E, Cooper W.
    BMC Cancer; 2016 Feb 26; 16():166. PubMed ID: 26921245
    [Abstract] [Full Text] [Related]

  • 31. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
    Navari RM.
    Future Oncol; 2010 Jul 26; 6(7):1073-84. PubMed ID: 20624119
    [Abstract] [Full Text] [Related]

  • 32. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial.
    Matsuura M, Satohisa S, Teramoto M, Tanaka R, Iwasaki M, Nishikawa A, Mizunuma M, Tanaka S, Hayakawa O, Saito T.
    J Obstet Gynaecol Res; 2015 Oct 26; 41(10):1607-13. PubMed ID: 26199182
    [Abstract] [Full Text] [Related]

  • 33. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM, Kim HJ, Choi YJ, Lee EM, Kim YS, Oh SY, Koh SJ, Baek JH, Lee WS, Joo YD, Lee HG, Yun EY, Chung JS.
    Support Care Cancer; 2016 Feb 26; 24(2):945-952. PubMed ID: 26265119
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients.
    Brugnatelli S, Gattoni E, Grasso D, Rossetti F, Perrone T, Danova M.
    Tumori; 2011 Feb 26; 97(3):362-6. PubMed ID: 21789017
    [Abstract] [Full Text] [Related]

  • 37. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
    van der Vorst MJDL, Toffoli EC, Beusink M, van Linde ME, van Voorthuizen T, Brouwer S, van Zweeden AA, Vrijaldenhoven S, Berends JC, Berkhof J, Verheul HMW.
    Oncologist; 2021 Jan 26; 26(1):e173-e181. PubMed ID: 32735029
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM.
    Expert Opin Drug Metab Toxicol; 2009 Dec 26; 5(12):1577-86. PubMed ID: 19929251
    [Abstract] [Full Text] [Related]

  • 40. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
    Kaushal J, Gupta MC, Kaushal V, Bhutani G, Dhankar R, Atri R, Verma S.
    Singapore Med J; 2010 Nov 26; 51(11):871-5. PubMed ID: 21140114
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.